Knight Therapeutics Announces an Exclusive Distribution Agreement for AzaSite(R) in Canada
MONTREAL, QUEBEC–(Marketwired – Jul 24, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”) a leading Canadian specialty pharmaceutical company, today announced the signing of an exclusive agreement with Akorn, Inc. (“Akorn”) of Lake Forest, Ill., for the exclusive distribution of AzaSite® in Canadian markets. Under the terms of the agreement with Akorn, Knight will handle all […]
Alimera Sciences Signs Knight Therapeutics as Exclusive ILUVIEN(R) Distributor for Canada
ATLANTA, GEORGIA and MONTREAL, QUEBEC–(Marketwired – Jul 21, 2015) – Alimera Sciences, Inc. (NASDAQ:ALIM) (“Alimera”), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has signed an exclusive agreement with Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, for the distribution in […]
Knight Lends a Hand to a New Debt Fund
MONTREAL, CANADA–(Marketwired – Jul 9, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has invested in the Bloom Burton Healthcare Lending Trust (the “Trust”) managed by Stratigis Capital Advisors Inc. Knight subscribed for $500,000 Trust units as part of a $15.9 million private placement. The Trust […]
Knight Amplifies Its Innovative Product Sourcing Strategy
MONTREAL, QUEBEC–(Marketwired – Jul 7, 2015) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries, (“Knight”) announced today that it has expanded its innovative pharmaceutical product sourcing strategy by entering into an agreement with TVM Capital Life Science to invest USD$1.6 million into TVM Life Sciences Venture VII (“TVM Fund”), a fund dedicated […]
Knight Finding NEMO: The Sequel
MONTREAL, CANADA–(Marketwired – Jul 2, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into an agreement with Sectoral Asset Management Inc. (“Sectoral”) to reinvest US$10 million into its New Emerging Medical Opportunities Fund III, Ltd. (“NEMO III”) life science fund. Knight’s investment in NEMO […]
Knight Extends Secured Loan
MONTREAL, CANADA–(Marketwired – Jun 26, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that it has extended a secured loan of $800,000 to Extenway Solutions Inc. (TSX:EY) (“Extenway”), an innovative provider of technology solutions for the healthcare industry. The secured loan of $800,000, which matures […]
Knight Creates Synergy With Sale of Neuragen(R) U.S.
MONTREAL, CANADA–(Marketwired – Jun 26, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into a sale agreement with Synergy Strips Corp (OTCQB:SNYR) (“Synergy”) related to the U.S. rights to Neuragen®, an innovative OTC product that helps relieve pain caused by diabetic […]
Chivalrous Knight Does Pro Bono
MONTREAL, QUEBEC–(Marketwired – Jun 26, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that it has (1) extended a secured loan of US$15 million to Pro Bono Bio PLC (“Pro Bono Bio”), the world’s leading healthcare nanotechnology company, and (2) entered into an exclusive distribution […]
Finding NEMO Yields Financial Return For Knight
MONTREAL, QUEBEC–(Marketwired – Jun 8, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that it has received a distribution of US$13.6 million related to its investment in Sectoral Asset Management Inc.’s (“Sectoral”) New Emerging Medical Opportunities Funds II, Ltd. (“NEMO II”) as part of a […]
Knight Secures Canadian Products in Two Separate Transactions
MONTREAL, CANADA–(Marketwired – Jun 4, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced the closing of two product transactions. 1. Knight secures its first Canadian product with modest existing sales Today, Knight acquired the assets related to Neuragen®, an innovative OTC product that helps relieve pain […]
